Dr. James F. Pingpank to Present at Leading Regional Therapies Conference
February 19 2009 - 8:24AM
PR Newswire (US)
NEW YORK, Feb. 19 /PRNewswire-FirstCall/ -- Delcath Systems, Inc.
(NASDAQ: DCTH), a medical technology company testing its
proprietary Percutaneous Hepatic Perfusion ("PHP(TM)") System for
the treatment of cancers of the liver, announced today that Dr.
James F. Pingpank will present at The Fourth International
Symposium on Regional Cancer Therapies, to be held February 21-23,
2009. (Logo:
http://www.newscom.com/cgi-bin/prnh/20081118/NY46990LOGO ) Dr.
Pingpank, Adjunct Principal Investigator of Delcath's Phase III
Trial treating ocular and cutaneous melanoma metastatic to the
liver, and Principal Investigator of the trial at the University of
Pittsburgh Medical Center, will deliver two oral presentations
titled: Impact of High-dose Melphalan (MEL) Administered via
Hepatic Arterial Infusion for Patients with Unresectable Hepatic
Metastases from Neuroendocrine Tumors (MNET) and
Multi-institutional Clinical Trials in Regional Therapy for Liver
Metastases Commenting on the relevance of these topics, Richard L.
Taney, President and CEO of Delcath Systems, stated, "As we move
toward completion of our pivotal Phase III Trial, Dr. Pingpank's
updates provide an invaluable communication to the other leaders in
the field of regional cancer treatment. Dr. Pingpank and Dr.
Marybeth Hughes, Principal Investigator of the Phase III Study at
the National Cancer Institute, continue to show their dedication to
the trial." The Phase III Study The Phase III clinical study is
being conducted under a Cooperative Research and Development
Agreement (CRADA) with the National Cancer Institute. This clinical
study is testing Delcath's PHP(TM) System for the regional delivery
of melphalan to the liver to treat patients with metastatic
cutaneous and ocular melanoma who have unresectable tumors in the
liver. The Delcath PHP System(TM) is designed to deliver
significantly higher doses of anti-cancer drugs to a patient's
liver while preventing entry of the drugs to the rest of the
patient's circulation. This isolation limits toxicities that result
from systemic chemotherapy treatments. Patients in the Phase III
trial initially are randomized into one of two treatment arms,
including immediate treatment with melphalan via the Delcath PHP
System(TM) or treatment with best alternative care. The study is
designed to evaluate the duration of tumor response in each of the
two study arms. Following guidelines established by U.S. Food and
Drug Administration under a Special Protocol Assessment (SPA), when
disease progresses in patients enrolled in the best alternative
care arm of the trial, they are permitted to "cross over" and
receive treatment with the Delcath System. The Fourth International
Symposium on Regional Cancer Therapies The Fourth International
Symposium on Regional Cancer Therapies will take place February
21-23, 2009 in Marco Island, Florida. The Symposium is sponsored by
the David C. Koch Regional Cancer Therapy Center, the University of
Pittsburgh School of Medicine Center for Continuing Education in
the Health Sciences and UPMC Cancer Centers. The Koch Regional
Cancer Therapy Center is committed to promoting research;
development and application of regional cancer therapies; and
exchanging information and promoting education among professionals
regarding regional cancer therapies. More information on this
conference can be found at http://www.regionaltherapies.com/. About
Delcath Systems, Inc. Delcath Systems, Inc. is a medical technology
company specializing in cancer treatment. The Company is testing a
proprietary, patented drug delivery system for the treatment of
liver cancers. Delcath's novel drug delivery platform is testing
the delivery of ultra-high doses of anti-cancer drugs to the liver
while preventing these high doses of drug from entering the
patient's bloodstream. The Company is currently enrolling patients
in Phase III and Phase II clinical studies for the treatment of
liver cancers using high doses of melphalan. The Company's
intellectual property portfolio consists of twenty-seven patents on
a worldwide basis including the U.S., Europe, Asia and Canada. For
more information, please visit the Company's website at
http://www.delcath.com/. The Private Securities Litigation Reform
Act of 1995 provides a safe harbor for forward-looking statements
made by the Company or on its behalf. This news release contains
forward-looking statements, which are subject to certain risks and
uncertainties that can cause actual results to differ materially
from those described. Factors that may cause such differences
include, but are not limited to, uncertainties relating to our
ability to successfully complete Phase III clinical trials and
secure regulatory approval of our current or future drug-delivery
system and uncertainties regarding our ability to obtain financial
and other resources for any research, development and
commercialization activities. These factors, and others, are
discussed from time to time in our filings with the Securities and
Exchange Commission. You should not place undue reliance on these
forward-looking statements, which speak only as of the date they
are made. We undertake no obligation to publicly update or revise
these forward-looking statements to reflect events or circumstances
after the date they are made.
http://www.newscom.com/cgi-bin/prnh/20081118/NY46990LOGO
http://photoarchive.ap.org/ DATASOURCE: Delcath Systems, Inc.
CONTACT: Richard Taney of Delcath Systems, Inc., +1-212-489-2100, ;
or Public Relations, Robin Wagge of Rubenstein Associates, Inc.,
+1-212-843-8006, , for Delcath Systems, Inc. Web Site:
http://www.delcath.com/ http://www.regionaltherapies.com/
Copyright